Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Septic Shock
Interventions
DRUG

Doripenem or Piperacillin/Tazobactam

"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."

DRUG

Doripenem or Piperacillin/Tazobactam

"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~* in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~* in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."

Trial Locations (1)

34295

Saint Eloi Intensive Care Unit - Montpellier University Hospital, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT01517815 - Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients | Biotech Hunter | Biotech Hunter